^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IL7R mutation

    i
    Other names: IL7R, Interleukin 7 Receptor, Interleukin-7 Receptor Subunit Alpha, IL-7 Receptor Subunit Alpha, L-7R Subunit Alpha, CD127 Antigen, IL-7R-Alpha, Interleukin 7 Receptor Isoform H5-6, Interleukin 7 Receptor Alpha Chain, CDW127, CDw127, IL-7RA, CD127, IL7RA, ILRA
    Entrez ID:
    3575
    Related biomarkers:
    Expression
    Fusion
    Others
    Apply
    A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (AALL1521) (NCT02723994)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    01/12/2024
    Initiation :
    09/30/2016
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3
    |
    CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion
    |
    cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia L-asparaginase)
    Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (NCT03571321)
    Phase 1
    University of Chicago
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    05/28/2019
    Primary completion :
    09/01/2026
    Completion :
    09/05/2027
    JAK2 • CRLF2 • IL7R • SH2B3
    |
    CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous
    HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C) (NCT05745714)
    Phase 1/2
    Princess Maxima Center for Pediatric Oncology
    Not yet recruiting
    Last update posted :
    02/27/2023
    Initiation :
    10/01/2023
    Primary completion :
    10/01/2030
    Completion :
    10/01/2030
    JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X
    |
    CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide